The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 ...

In this CE activity, expert faculty identify the challenges associated with anti-VEGF use in patients with nAMD, describe the rationale for targeting tyrosine kinases, and review the most recent ...

Incorporate omega-3s into your diet: Foods like fish have been shown to reduce the risk of macular degeneration. Don’t forget to add a handful of walnuts to your meals as they’re also packed with ...

In this CE activity, expert faculty summarize the challenges associated with anti-VEGF use, review the rationale for targeting tyrosine kinases in nAMD and DR, and summarize the most recent ...

TH103 was specifically engineered to address the limitations of current neovascular Age-related Macular Degeneration (“nAMD”) therapies and has demonstrated both potent anti-VEGF activity and ...

TH103 was specifically engineered to address the limitations of current neovascular Age-related Macular Degeneration (“nAMD”) therapies and has demonstrated both potent anti-VEGF activity and ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...